NCT06059001View on ClinicalTrials.gov

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered Iv in Patients with PDAC

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

OMO-103

Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion

DRUG

Nab-Paclitaxel

IV infusion - Standard of Care

DRUG

Gemcitabine

IV infusion - Standard of Care

Trial Locations (6)

5009

RECRUITING

Hospital Miguel Servet, Zaragoza

28007

RECRUITING

Hospital Gregorio Marañon, Madrid

29010

RECRUITING

Hospital Regional Universitario de Málaga, Málaga

39008

RECRUITING

Hospital Universitario Marqués de Valdecilla, Santander

08035

RECRUITING

Hospital Vall d´Hebrón, Barcelona

08908

RECRUITING

ICO Hopsitalet, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

Peptomyc S.L.
All Listed Sponsors
lead

Peptomyc S.L.

INDUSTRY

NCT06059001 - Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered Iv in Patients with PDAC | Biotech Hunter | Biotech Hunter